Unlock the Full Potential of Proximity-Based Modalities by Validating Novel MoAs & Optimizing Chemical Structures to Radically Advance Induced Proximity Beyond Proteasomal Degradation
5th Annual Induced Proximity-Based Drug Discovery Summit
The rapid therapeutic success of PROTACs and Molecular Glue Degraders has underpinned a surge in new proximity-based modalities with the ability to treat a wide array of previously undruggable diseases. Last year alone there was a 72% increase in the number of induced proximity assets on Beacon by Hanson Wade.
Additionally, with significant funding - from a $186 million partnership between Photys Tx and Novo Nordisk, to the launch of new companies such as General Proximity and Outrun – the induced proximity field is experiencing unprecedented momentum, accelerating the next wave of novel drugs through discovery and translational pipeline for clinical validation.
Coming to San Diego, CA for the first time, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable.
Enabling leaders in biopharma and academia to identify novel MoAs, leverage advanced technologies to find targets more efficiently, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs, RIPTACs, tPRIMEs, RiboTACs and more, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective, potent small molecules of tomorrow.
Join experts in drug discovery, medicinal chemistry, chemical biology and structural biology from leading companies such as Genentech, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system.
Attending Companies Include:
What's New?
Next-Gen MoAs & Expanded Therapeutic Scope – Cutting-edge insights into RIPTACs, DUBTACs, RIBOTACs, tPRIMEs, Non-degrading Molecular Glues, and novel protein stabilizers, with a focus on improving selectivity, safety, and clinical viability.
Exclusive AI & Machine Learning Insights – Deep-dive sessions from Genentech, Arrakis, Novo Nordisk & Vicinitas showcasing how AI-driven modeling, active learning, and bioinformatics are optimizing target discovery, validation, and ternary complex optimization.
New Speaker Lineup & Industry Leaders – Fresh insights from Halda, Photys, Stablix, Novartis, Harvard, A-Alpha, Plexium and more, to enable you to walk away with the tools to accelerate your induced proximity candidates to the clinic.
Deep-Dive into Investment Strategies – Dedicated Investment Roundtable with Astellas Ventures to explore how biotech, academia, and pharma can position their induced proximity assets to secure funding and de-risk clinical translation.
Induced Proximity Expert Speakers Include:
Other events in the Small Molecules & TPD World Series
